✦ LIBER ✦

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

✍ Scribed by Muralidhar Beeram; Ian E. Krop; Howard A. Burris; Sandhya R. Girish; Wei Yu; Michael W. Lu; Scott N. Holden; Shanu Modi

Book ID: 112067211
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 417 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.27622

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Randomized Study of Trastuzumab

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

✍ Hurvitz, S. A.; Dirix, L.; Kocsis, J.; Bianchi, G. V.; Lu, J.; Vinholes, J.; Gua 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

Ado-trastuzumab emtansine (T-DM1) in hum

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential

✍ Peddi, P. F.; Hurvitz, S. A. 📂 Article 📅 2014 🏛 SAGE Publications 🌐 English ⚖ 425 KB

Phase IIa Trial of Trastuzumab Emtansine

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer

✍ Miller, K. D.; Dieras, V.; Harbeck, N.; Andre, F.; Mahtani, R. L.; Gianni, L.; A 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 148 KB

Pertuzumab Monotherapy After Trastuzumab

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

✍ Cortes, J.; Fumoleau, P.; Bianchi, G. V.; Petrella, T. M.; Gelmon, K.; Pivot, X. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 497 KB

A population pharmacokinetic/pharmacodyn

A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer

✍ Bender, Brendan C.; Schaedeli-Stark, Franziska; Koch, Reinhold; Joshi, Amita; Ch 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 755 KB

Phase II Study of the Antibody Drug Conj

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy

✍ Burris, H. A.; Rugo, H. S.; Vukelja, S. J.; Vogel, C. L.; Borson, R. A.; Limenta 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 176 KB